Rachel McMinn
Chief Executive Officer
Neurogene
Neurogene develops gene therapies targeting rare neurological disorders, utilizing adeno-associated virus (AAV) vectors to deliver therapeutic genes directly to affected cells. The company aims to improve patient outcomes for conditions like Rett syndrome, where current treatment options are limited and often ineffective.
- Biotechnology
Updated 7 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Problem
Many rare neurological disorders lack effective treatments, leaving patients with limited options to manage their conditions. Current therapies often fail to address the underlying genetic causes of these diseases, resulting in suboptimal outcomes.
Solution
Neurogene develops gene therapies that target the genetic roots of rare neurological disorders. The company uses adeno-associated virus (AAV) vectors to deliver functional genes directly to affected cells, aiming to restore normal cellular function and improve patient outcomes. Their approach focuses on creating life-changing genetic medicines for individuals and families affected by these devastating diseases. By addressing the underlying genetic defects, Neurogene seeks to provide more effective and potentially curative treatments for conditions with high unmet medical needs.
Target Audience
The primary target audience includes patients and their families affected by rare neurological disorders, as well as healthcare providers specializing in these conditions.
Features
- Utilizes adeno-associated virus (AAV) vectors for targeted gene delivery.
- Focuses on developing therapies for rare neurological disorders with limited treatment options.
- Aims to correct the underlying genetic causes of diseases at the cellular level.
- Pipeline includes gene therapy programs targeting specific neurological conditions.